Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:53:56 EST Tue 02 Dec 2025
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q1.00.7093·0.7160.20.7091-0.0329-4.4708.44596930.7293  0.7455  0.68861.3099  0.552611:37:2808:0015 min RT 2¢

Recent Trades - Last 10 of 693
Time ETExPriceChangeVolume
11:37:28Q0.7104-0.03166
11:35:55Q0.7055-0.03659
11:35:52Q0.708-0.03494
11:35:52Q0.7091-0.03294
11:35:26Q0.7091-0.0329500
11:33:47Q0.7057-0.03631
11:33:35Q0.7054-0.03662
11:32:46Q0.7018-0.0402100
11:32:46Q0.7018-0.0402200
11:32:46Q0.7018-0.0402100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-02 08:00U:ATOSNews ReleaseInsilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
2025-11-17 09:07U:ATOSNews ReleaseAtossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
2025-11-12 08:15U:ATOSNews ReleaseAtossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
2025-11-06 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
2025-10-21 08:00U:ATOSNews ReleaseAtossa Therapeutics Highlights Progress in RECAST(TM) DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
2025-10-15 08:00U:ATOSNews ReleaseAtossa Therapeutics to Present at the Maxim Growth Summit 2025
2025-10-14 08:00U:ATOSNews ReleaseAtossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
2025-10-13 08:00U:ATOSNews ReleaseAtossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
2025-10-06 08:00U:ATOSNews ReleaseAtossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
2025-10-01 08:30U:ATOSNews ReleaseAtossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
2025-09-17 08:00U:ATOSNews ReleaseAtossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
2025-09-08 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
2025-08-28 08:30U:ATOSNews ReleaseAtossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
2025-08-20 08:30U:ATOSNews ReleaseAtossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
2025-08-12 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
2025-07-29 07:45U:ATOSNews ReleaseAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
2025-06-02 08:45U:ATOSNews ReleaseAtossa Therapeutics to Present at the Jefferies Global Healthcare Conference
2025-05-20 09:02U:ATOSNews ReleaseJoin Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
2025-05-14 08:15U:ATOSNews ReleaseAtossa Therapeutics Announces Full Results from I-SPY2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen
2025-05-13 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update